Skip to main content
Journal cover image

Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency.

Publication ,  Journal Article
Hicks, ED; Hall, G; Hershfield, MS; Tarrant, TK; Bali, P; Sleasman, JW; Buckley, RH; Mousallem, T
Published in: J Clin Immunol
April 27, 2024

PURPOSE: Patients with adenosine deaminase 1 deficient severe combined immunodeficiency (ADA-SCID) are initially treated with enzyme replacement therapy (ERT) with polyethylene glycol-modified (PEGylated) ADA while awaiting definitive treatment with hematopoietic stem cell transplant (HSCT) or gene therapy. Beginning in 1990, ERT was performed with PEGylated bovine intestinal ADA (ADAGEN®). In 2019, a PEGylated recombinant bovine ADA (Revcovi®) replaced ADAGEN following studies in older patients previously treated with ADAGEN for many years. There are limited longitudinal data on ERT-naïve newborns treated with Revcovi. METHODS: We report our clinical experience with Revcovi as initial bridge therapy in three newly diagnosed infants with ADA-SCID, along with comprehensive biochemical and immunologic data. RESULTS: Revcovi was initiated at twice weekly dosing (0.2 mg/kg intramuscularly), and monitored by following plasma ADA activity and the concentration of total deoxyadenosine nucleotides (dAXP) in erythrocytes. All patients rapidly achieved a biochemically effective level of plasma ADA activity, and red cell dAXP were eliminated within 2-3 months. Two patients reconstituted B-cells and NK-cells within the first month of ERT, followed by naive T-cells one month later. The third patient reconstituted all lymphocyte subsets within the first month of ERT. One patient experienced declining lymphocyte counts with improvement following Revcovi dose escalation. Two patients developed early, self-resolving thrombocytosis, but no thromboembolic events occurred. CONCLUSION: Revcovi was safe and effective as initial therapy to restore immune function in these newly diagnosed infants with ADA-SCID, however, time course and degree of reconstitution varied. Revcovi dose may need to be optimized based on immune reconstitution, clinical status, and biochemical data.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Immunol

DOI

EISSN

1573-2592

Publication Date

April 27, 2024

Volume

44

Issue

5

Start / End Page

107

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Severe Combined Immunodeficiency
  • Recombinant Proteins
  • Male
  • Infant, Newborn
  • Infant
  • Immunology
  • Immune Reconstitution
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hicks, E. D., Hall, G., Hershfield, M. S., Tarrant, T. K., Bali, P., Sleasman, J. W., … Mousallem, T. (2024). Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency. J Clin Immunol, 44(5), 107. https://doi.org/10.1007/s10875-024-01710-z
Hicks, Elizabeth Daly, Geoffrey Hall, Michael S. Hershfield, Teresa K. Tarrant, Pawan Bali, John W. Sleasman, Rebecca H. Buckley, and Talal Mousallem. “Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency.J Clin Immunol 44, no. 5 (April 27, 2024): 107. https://doi.org/10.1007/s10875-024-01710-z.
Hicks ED, Hall G, Hershfield MS, Tarrant TK, Bali P, Sleasman JW, et al. Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency. J Clin Immunol. 2024 Apr 27;44(5):107.
Hicks, Elizabeth Daly, et al. “Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency.J Clin Immunol, vol. 44, no. 5, Apr. 2024, p. 107. Pubmed, doi:10.1007/s10875-024-01710-z.
Hicks ED, Hall G, Hershfield MS, Tarrant TK, Bali P, Sleasman JW, Buckley RH, Mousallem T. Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency. J Clin Immunol. 2024 Apr 27;44(5):107.
Journal cover image

Published In

J Clin Immunol

DOI

EISSN

1573-2592

Publication Date

April 27, 2024

Volume

44

Issue

5

Start / End Page

107

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Severe Combined Immunodeficiency
  • Recombinant Proteins
  • Male
  • Infant, Newborn
  • Infant
  • Immunology
  • Immune Reconstitution
  • Humans
  • Female